Everything tagged "pipeline" across research, earnings, and macro.
3 articles
Moderna’s latest surge looks earned, not speculative. Science Day gave the market a concrete post-COVID roadmap, and the August 5 flu decision gives MRNA a real catalyst investors can actually underwrite.
Moderna is a transition story with real mRNA platform strength, but weak earnings and heavy COVID dependence keep it in Hold territory. The stock’s appeal hinges on late-stage pipeline catalysts and a cash runway that supports the pivot.
Regeneron combines a durable cash engine with a broad pipeline, while Dupixent growth and EYLEA HD adoption help offset legacy EYLEA biosimilar pressure. The stock screens as a Buy with valuation still reasonable for a mature biotech compounder.
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the Generator